FDA Orange Book · active-ingredient family
Carbidopa
Carbidopa is approved as 1 brand and 7 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.
Reference-listed drug:LODOSYN · NDA 017830
1
Brand (NDA)
7
Generics (ANDA)
0
Listed patents
0
Exclusivity periods
Brand (NDA) products · tablet
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| LODOSYNRLD | ATON | NDA 017830 | AB | Approved Prior to Jan 1, 1982 |
Generic (ANDA) products (7)
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| CARBIDOPA | REGCON HOLDINGS | ANDA 217961 | AB | Dec 11, 2023 | |
| CARBIDOPA | AUROBINDO PHARMA | ANDA 211055 | AB | Oct 21, 2019 | |
| CARBIDOPA | ZYDUS PHARMS | ANDA 209910 | AB | May 07, 2018 | |
| CARBIDOPA | NOVEL LABS INC | ANDA 204763 | AB | Oct 20, 2017 | |
| CARBIDOPA | EDENBRIDGE PHARMS | ANDA 205304 | AB | Feb 17, 2016 | |
| CARBIDOPA | ALVOGEN | ANDA 204291 | — | Jan 08, 2016 | |
| CARBIDOPA | ANI PHARMS | ANDA 203261 | — | Mar 10, 2014 |
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Carbidopa — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
